NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether.
Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin
Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncolog
The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least
Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the
Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with